NS 8

Drug Profile

NS 8

Latest Information Update: 22 Jan 2007

Price : $50

At a glance

  • Originator Nippon Shinyaku
  • Class Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 16 Jan 2007 Discontinued - Phase-II for Overactive bladder in Europe (unspecified route)
  • 16 Jan 2007 Discontinued - Phase-I for Overactive bladder in Japan (unspecified route)
  • 08 May 2006 This compound is still in active development for Overactive bladder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top